Free Trial
Robert Driscoll

Robert Driscoll Analyst Performance

Senior Vice President, Equity Research at Wedbush

Robert Driscoll is a stock analyst at Wedbush focused in the medical sector, covering 26 publicly traded companies. Over the past year, Robert Driscoll has issued 45 stock ratings, including buy, hold, and sell recommendations. While full access to Robert Driscoll's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Driscoll's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
57 Last 8 Years
Buy Recommendations
77.19% 44 Buy Ratings
Companies Covered
26 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy77.2%44 ratings
Hold15.8%9 ratings
Sell7.0%4 ratings

Out of 57 total stock ratings issued by Robert Driscoll at Wedbush, the majority (77.2%) have been Buy recommendations, followed by 15.8% Hold and 7.0% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
96.2% of companies on NASDAQ
25 companies
NYSE
3.8% of companies on NYSE
1 company

Robert Driscoll, an analyst at Wedbush, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
25 companies
96.2%
Manufacturing
1 company
3.8%

Robert Driscoll of Wedbush specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
21 companies
80.8%
MED - DRUGS
4 companies
15.4%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
3.8%

About Robert Driscoll

Robert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS). Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.
Follow on LinkedIn

Robert Driscoll's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
5/14/2026Lower Price Target$19.85$34.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
5/14/2026Boost Price Target$23.72$33.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
5/14/2026Lower Price Target$0.90$6.00Outperform
EIKN
EIKN
5/12/2026Lower Price Target$9.95$5.00Underperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
5/8/2026Boost Price Target$14.96$37.00Outperform
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
5/8/2026Lower Price Target$14.30$36.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
5/7/2026Boost Price Target$144.46$165.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
5/6/2026Boost Price Target$16.26$40.00Outperform
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
5/5/2026Initiated Coverage$1.76$6.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4/14/2026Boost Price Target$30.82$58.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/14/2026Reiterated Rating$138.88Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
4/13/2026Reiterated Rating$4.77$2.00Neutral
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
4/2/2026Boost Price Target$21.89$41.00Outperform
EIKN
EIKN
3/31/2026Reiterated Rating$10.03$7.00Underperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3/31/2026Reiterated Rating$33.36$52.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3/31/2026Reiterated Rating$0.74$7.00Outperform
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
3/17/2026Boost Price Target$2.19$14.00Outperform
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3/17/2026Boost Price Target$6.75$11.00Outperform
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3/12/2026Reiterated Rating$4.87$10.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3/11/2026Boost Price Target$14.91$36.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/9/2026Reiterated Rating$21.20$21.50Neutral
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3/6/2026Lower Price Target$8.51$36.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3/6/2026Boost Price Target$16.80$19.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/6/2026Downgrade$21.20Hold
EIKN
EIKN
2/26/2026Initiated Coverage$14.89$7.00Underperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/25/2026Boost Price Target$12.02$30.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
2/24/2026Boost Price Target$11.99$11.00Neutral
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2/18/2026Boost Price Target$30.76$52.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2/13/2026Boost Price Target$29.60$53.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2/10/2026Lower Price Target$0.64$7.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
2/4/2026Boost Price Target$7.35$19.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
1/9/2026Reiterated Rating$107.39Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12/16/2025Boost Price Target$22.12$37.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
12/11/2025Initiated Coverage$41.74$70.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
12/9/2025Boost Price Target$12.44$34.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
11/14/2025Reiterated Rating$10.68$38.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
11/6/2025Boost Price Target$59.34$80.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
10/20/2025Upgrade$4.50$18.00Outperform
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
10/20/2025Boost Price Target$19.32$38.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
10/17/2025Reiterated Rating$49.68$77.00Outperform
Millionaire warns: Move your money now (Ad)

Larry Benedict, the hedge fund trader who generated $274 million in profits for clients and beat the S&P 500 by 18 times in 2025, says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. Benedict's track record around Fed moves is hard to ignore - 62% from a single position after 2020 rate cuts, 117% in under a month when rate hikes were signaled in 2022, and an 89% gain in 17 days following a Jackson Hole speech. He has already identified the one ticker he believes will be at the center of the coming money flows, and he's sharing it free.tc pixel

Click here to see the ticker Larry Benedict is recommending right now
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
9/11/2025Boost Price Target$40.45$77.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/22/2025Reiterated Rating$3.14$4.00Neutral
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
7/14/2025Initiated Coverage$12.96$27.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6/20/2025Reiterated Rating$6.06$36.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
5/15/2025Reiterated Rating$1.18$4.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
5/9/2025Lower Price Target$0.82$6.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/28/2025Reiterated Rating$41.02$67.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
3/28/2025Reiterated Rating$1.70$4.00Neutral
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
3/20/2025Reiterated Rating$7.06$17.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
3/12/2025Downgrade$8.30$12.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3/12/2025Reiterated Rating$1.30$8.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/26/2025Reiterated Rating$10.25$32.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2/6/2025Boost Price Target$8.13$36.00Outperform